Literature DB >> 21715580

Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis.

Puiying A Mak1, George F Santos, Kelly-Anne Masterman, Jeff Janes, Bill Wacknov, Kay Vienken, Marzia Giuliani, Ann E Herman, Michael Cooke, M Lamine Mbow, John Donnelly.   

Abstract

Complement-mediated bactericidal activity has long been regarded as the serological correlate of protective immunity against Neisseria meningitidis. This was affirmed in 2005 at a WHO-sponsored meningococcal serology standardization workshop. The assay currently employed by most laboratories involves determining surviving bacterial colony counts on agar as a readout which is labor-intensive, time-consuming, and not amendable to rapid data analysis for clinical trials. Consequently, there is an acute need to develop a sensitive, high-throughput bactericidal assay to enable a rapid and robust assessment of the effectiveness of vaccine candidates. To this end, we have developed an automated, kinetic assay based on the fluorescent respiration product of resazurin which reduces assay volume, shortens assay time, and facilitates automation of data analysis. We demonstrate proof of concept for applicability of this high-throughput system with multiple meningococcal strains and utilizing different lots of human complement. The assay is robust and highly reproducible. Titers obtained by the fluorescence readout method are strongly correlated with the data obtained using the conventional, agar plate-based assay. These results demonstrate that the detection of bacteria that have survived the bactericidal reaction by measuring metabolic activity using a fluorescent dye as an alternative readout is a promising approach for the development of a high-throughput bactericidal assay.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715580      PMCID: PMC3147359          DOI: 10.1128/CVI.05028-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

1.  Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.

Authors:  Sandra Romero-Steiner; Willie Spear; Nekeidra Brown; Patricia Holder; Thomas Hennessy; Patricia Gomez De Leon; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Validation of colorimetric assay to detect complement-mediated antibody-dependent bactericidal activity against serogroups B and C Neisseria meningitidis.

Authors:  Tamara Rodríguez; Miriam Lastre; Bárbara Cedré; Esther María Fajardo; Judith del Campo; Ileana Delgado; Gustavo Sierra; Oliver Pérez
Journal:  Biologicals       Date:  2003-09       Impact factor: 1.856

3.  Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.

Authors:  Ray Borrow; Ingeborg S Aaberge; George F Santos; T Lynn Eudey; Philipp Oster; Anne Glennie; Jamie Findlow; E Arne Høiby; Einar Rosenqvist; Paul Balmer; Diana Martin
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

4.  Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

Authors:  R Borrow; G M Carlone; N Rosenstein; M Blake; I Feavers; D Martin; W Zollinger; J Robbins; I Aaberge; D M Granoff; E Miller; B Plikaytis; L van Alphen; J Poolman; R Rappuoli; L Danzig; J Hackell; B Danve; M Caulfield; S Lambert; D Stephens
Journal:  Vaccine       Date:  2006-06-12       Impact factor: 3.641

5.  Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

Authors:  Marzia M Giuliani; Alessia Biolchi; Davide Serruto; Francesca Ferlicca; Kay Vienken; Philipp Oster; Rino Rappuoli; Mariagrazia Pizza; John Donnelly
Journal:  Vaccine       Date:  2010-05-21       Impact factor: 3.641

6.  Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.

Authors:  Daniela Toneatto; Philipp Oster; A Corine W deBoer; Amy Emerson; George F Santos; Ellen Ypma; Lisa DeTora; Mariagrazia Pizza; Alan Kimura; Peter Dull
Journal:  Hum Vaccin       Date:  2011-07-01

7.  Effects of serum protein and colloid on the alamarBlue assay in cell cultures.

Authors:  P Goegan; G Johnson; R Vincent
Journal:  Toxicol In Vitro       Date:  1995-06       Impact factor: 3.500

Review 8.  Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.

Authors:  Diana Lennon; Catherine Jackson; Sharon Wong; Maraekura Horsfall; Joanna Stewart; Stewart Reid
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

9.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Authors:  G V Sierra; H C Campa; N M Varcacel; I L Garcia; P L Izquierdo; P F Sotolongo; G V Casanueva; C O Rico; C R Rodriguez; M H Terry
Journal:  NIPH Ann       Date:  1991-12

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  11 in total

1.  Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.

Authors:  Xavier Saez-Llorens; Diana Catalina Aguilera Vaca; Katia Abarca; Emmanuelle Maho; Maria Gabriela Graña; Esther Heijnen; Igor Smolenov; Peter M Dull
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Increasing the High Throughput of a Luminescence-Based Serum Bactericidal Assay (L-SBA).

Authors:  Maria Grazia Aruta; Martina Carducci; Francesca Micoli; Francesca Necchi; Omar Rossi
Journal:  BioTech (Basel)       Date:  2021-09-18

3.  Bioprospecting the American alligator (Alligator mississippiensis) host defense peptidome.

Authors:  Barney M Bishop; Melanie L Juba; Megan C Devine; Stephanie M Barksdale; Carlos Alberto Rodriguez; Myung C Chung; Paul S Russo; Kent A Vliet; Joel M Schnur; Monique L van Hoek
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

4.  Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout.

Authors:  Francesca Necchi; Allan Saul; Simona Rondini
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

5.  Optimization of a High-Throughput 384-Well Plate-Based Screening Platform with Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 15442 Biofilms.

Authors:  Shella Gilbert-Girard; Kirsi Savijoki; Jari Yli-Kauhaluoma; Adyary Fallarero
Journal:  Int J Mol Sci       Date:  2020-04-25       Impact factor: 5.923

Review 6.  A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines.

Authors:  Jamie Findlow; Paul Balmer; Ray Borrow
Journal:  Hum Vaccin Immunother       Date:  2019-04-23       Impact factor: 3.452

7.  Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.

Authors:  Xavier Sáez-Llorens; Johnny Beltran-Rodriguez; Jose M Novoa Pizarro; Ilhem Mensi; Pavitra Keshavan; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452

8.  A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A.

Authors:  Jacopo Enotarpi; Marta Tontini; Cristiana Balocchi; Daan van der Es; Ludovic Auberger; Evita Balducci; Filippo Carboni; Daniela Proietti; Daniele Casini; Dmitri V Filippov; Hermen S Overkleeft; Gijsbert A van der Marel; Cinzia Colombo; Maria Rosaria Romano; Francesco Berti; Paolo Costantino; Jeroen D C Codeé; Luigi Lay; Roberto Adamo
Journal:  Nat Commun       Date:  2020-09-07       Impact factor: 14.919

9.  Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.

Authors:  Timo Vesikari; Jerzy Brzostek; Anitta Ahonen; Marita Paassilta; Ewa Majda-Stanislawska; Leszek Szenborn; Miia Virta; Robert Clifford; Teresa Jackowska; Murray Kimmel; Ilaria Bindi; Pavitra Keshavan; Paola Pedotti; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2021-09-28       Impact factor: 3.452

10.  Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.

Authors:  Carmen I Baccarini; Michael W Simon; Donald Brandon; Shane Christensen; Emilia Jordanov; Mandeep S Dhingra
Journal:  Pediatr Infect Dis J       Date:  2020-10       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.